Ï㽶ÊÓƵ

Journal Article

1. Lehmann CJ, Dylla NP, Odenwald M, Nayak R, Khalid M, Boissiere J, Cantoral J, Adler E, Stutz MR, Dela Cruz M, Moran A, Lin H, Ramaswamy R, Sundararajan A, Sidebottom AM, Little J, Pamer EG, Aronsohn A, Fung J, Baker TB, Kacha A (2023). Fecal metabolite profiling identifies liver transplant recipients at risk for postoperative infection. Cell Host Microbe, 32(1), 117-130.e4. ()
2. Nwaduru C, Baker E, Buff M, Selim M, Ovalle LA, Baker TB, Zimmerman MA (2024). Assessing Liver Viability: Insights From Mitochondrial Bioenergetics in Ischemia-Reperfusion Injury. Transplant Proc, 56(1), 228-235. ()
3. Sarwal A, Yamauchi J, Raghavan D, Shihab F, Fornadi K, Rofaiel G, Zimmerman M, Campsen J, Baker N, Akhila Ganireddy Y, Aviles-Ovalle L, Baker T, Hall IE, Molnar MZ (2023). Throwing stones: kidney stone incidence in living kidney donor candidates with increased metabolic risk. Ren Fail, 45(1), 2226763. ()
4. Yamauchi J, Raghavan D, Rofaiel G, Zimmerman M, Potluri VS, Baker T, Campsen J, Hall IE, Molnar MZ (2023). Therapeutic Donor Kidney Transplant Outcomes: Comparing Early US Experiences Using Optimal Matching. Transplant Direct, 9(12), e1554. ()
5. Yu Q, Patel M, Kwak D, Ungchusri E, Wang Y, Van Ha T, Zangan S, Marshall E, Little K, Baker T, Liao CY, Pillai A, Ahmed O (2023). Segmental Yttrium-90 Radioembolization Using Glass Microspheres Greater than 400 Gray for the Treatment of Intrahepatic Cholangiocarcinoma: A Preliminary Experience. J Vasc Interv Radiol, 34(11), 1970-1976.e1. ()
6. Yamauchi J, Azhar A, Hall IE, Bhalla A, Potluri VS, Tanriover B, Gupta G, Imlay H, Truax C, Balaraman V, Raghavan D, Zimmerman M, Campsen J, Rofaiel G, Baker T, Molnar MZ (2023). Comparison of Short-Term Outcomes in Kidney Transplant Recipients from SARS-CoV-2-Infected versus Noninfected Deceased Donors. Clin J Am Soc Nephrol, 18(11), 1466-1475. ()
7. Kagawa H, Goodwin M, Stehlik J, Campsen J, Baker T, Selzman CH (2023). A Case Report of Triple Organ Transplantation From a Donor After Circulatory Death Using Thoraco-Abdominal Normothermic Regional Perfusion. Transplant Proc, 55(8), 1883-1887. ()
8. Ahmed O, Yu Q, Patel M, Hwang G, Pillai A, Liao CY, Fung J, Baker T (2022). Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as the First-Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma. J Vasc Interv Radiol, 34(4), 702-709. ()
9. Kim P, Littau M, Baker TB, Abdelsattar Z, Tonelli C, Bunn C, Kulshrestha S, Luchette FA, Scaglione S, Baker MS (2022). The benefit of liver transplant beyond Milan criteria: An analysis using the National Cancer Database. Surgery, 172(6), 1823-1828. ()
10. Talwar A, Varghese J, Knight GM, Katariya N, Caicedo JC, Dietch Z, Borja-Cacho D, Ladner D, Christopher D, Baker T, Abecassis M, Mouli S, Desai K, Riaz A, Thornburg B, Salem R (2022). Preoperative portal vein recanalization-transjugular intrahepatic portosystemic shunt for chronic obliterative portal vein thrombosis: Outcomes following liver transplantation. Hepatol Commun, 6(7), 1803-1812. ()
11. Perez-Gutierrez A, Siddiqi U, Kim G, Rangrass G, Kacha A, Jeevanandam V, Becker Y, Potter L, Fung J, Baker TB (2022). Combined heart-liver-kidney transplant: The university of Chicago medicine experience. Clin Transplant, 36(4), e14586. ()
12. Kim P, Littau M, Baker TB, Abdelsattar Z, Tonelli C, Bunn C, Kulshrestha S, Luchette FA, Baker MS (2021). Intrahepatic cholangiocarcinoma: Is there a role for liver transplantation? Surgery, 171(3), 741-746. ()
13. Strauss AT, Boyarsky BJ, Garonzik-Wang JM, Werbel W, Durand CM, Avery RK, Jackson KR, Kernodle AB, Baker T, Snyder J, Segev DL, Massie AB (2020). Liver transplantation in the United States during the COVID-19 pandemic: National and center-level responses. Am J Transplant, 21(5), 1838-1847. ()
14. Jayant K, Reccia I, Virdis F, Pyda JS, Bachul PJ, di Sabato D, Barth RN, Fung J, Baker T, Witkowski P (2021). COVID-19 in hospitalized liver transplant recipients: An early systematic review and meta-analysis. Clin Transplant, 35(4), e14246. ()
15. Gabr A, Kulik L, Mouli S, Riaz A, Ali R, Desai K, Mora RA, Ganger D, Maddur H, Flamm S, Boike J, Moore C, Thornburg B, Alasadi A, Baker T, Borja-Cacho D, Katariya N, Ladner DP, Caicedo JC, Lewandowski RJ, Salem R (2020). Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort. Hepatology, 73(3), 998-1010. ()
16. Badar W, Van Ha T, Zangan S, Navuluri R, Pillai A, Baker T, Dalag L, Han R, Ahmed O (2021). Safety and efficacy of repeat Y90 radioembolization to the same hepatic arterial territory. Br J Radiol, 94(1119), 20200752. ()
17. Boyarsky BJ, Ruck JM, Chiang TP, Werbel WA, Strauss AT, Getsin SN, Jackson KR, Kernodle AB, Van Pilsum Rasmussen SE, Baker TB, Al Ammary F, Durand CM, Avery RK, Massie AB, Segev DL, Garonzik-Wang JM (2020). Evolving Impact of COVID-19 on Transplant Center Practices and Policies in the United States. Clin Transplant, 34(12), e14086. ()
18. Soubrane O, Eguchi S, Uemoto S, Kwon CHD, Wakabayashi G, Han HS, Kim KH, Troisi RI, Cherqui D, Rotellar F, Cauchy F, Soyama A, Ogiso S, Choi GS, Takahara T, Cho JY, Cho HD, Vanlander A, Pittau G, Scatton O, Pardo F, Baker T (2020). Minimally Invasive Donor Hepatectomy for Adult Living Donor Liver Transplantation: An International, Multi-Institutional Evaluation of Safety, Efficacy and Early Outcomes. Ann Surg. ()
19. Ahmed O, Salaskar AL, Zangan S, Pillai A, Baker T (2020). Transsplenic portal vein recanalization and direct intrahepatic portosystemic shunt placement to optimize liver transplantation. CVIR Endovasc, 3(1), 5. ()
20. Gabr A, Abouchaleh N, Ali R, Baker T, Caicedo J, Katariya N, Abecassis M, Riaz A, Lewandowski RJ, Salem R (2018). Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma. J Vasc Interv Radiol, 29(11), 1502-1510.e1. ()
21. Bodzin AS, Baker TB (2018). Liver Transplantation Today: Where We Are Now and Where We Are Going. Liver Transpl, 24(10), 1470-1475. ()
22. Benjamin AJ, Baker TB, Talamonti MS, Bodzin AS, Schneider AB, Winschester DJ, Roggin KK, Bentrem DJ, Suss NR, Baker MS (2018). Liver transplant offers a survival benefit over margin negative resection in patients with small unifocal hepatocellular carcinoma and preserved liver function. Surgery, 163(3), 582-586. ()
23. Kallini JR, Gabr A, Ali R, Abouchaleh N, Riaz A, Baker T, Kulik L, Caicedo J, Salem R, Lewandowski RJ (2017). Pretransplant Intra-arterial Liver-Directed Therapy Does Not Increase the Risk of Hepatic Arterial Complications in Liver Transplantation: A Single-Center 10-Year Experience. Cardiovasc Intervent Radiol, 41(2), 231-238. ()
24. Baker TB, Zimmerman MA, Goodrich NP, Samstein B, Pomfret EA, Pomposelli JJ, Gillespie BW, Berg CL, Emond JC, Merion RM (2017). Biliary reconstructive techniques and associated anatomic variants in adult living donor liver transplantations: The adult-to-adult living donor liver transplantation cohort study experience. Liver Transpl, 23(12), 1519-1530. ()
25. Thornburg B, Desai K, Hickey R, Hohlastos E, Kulik L, Ganger D, Baker T, Abecassis M, Caicedo JC, Ladner D, Fryer J, Riaz A, Lewandowski RJ, Salem R (2017). Pretransplantation Portal Vein Recanalization and Transjugular Intrahepatic Portosystemic Shunt Creation for Chronic Portal Vein Thrombosis: Final Analysis of a 61-Patient Cohort. J Vasc Interv Radiol, 28(12), 1714-1721.e2. ()
26. Liu JB, Baker TB, Suss NR, Talamonti MS, Roggin KK, Winchester DJ, Baker MS (2017). Orthotopic liver transplantation provides a survival advantage compared with resection in patients with hepatocellular carcinoma and preserved liver function. Surgery, 162(5), 1032-1039. ()
27. Emond JC, Goodrich NP, Pomposelli JJ, Baker TB, Humar A, Grant DR, Abt P, Friese CE, Fisher RA, Kam I, Sherker AH, Gillespie BW, Merion RM (2017). Hepatic Hemodynamics and Portal Flow Modulation: The A2ALL Experience. Transplantation, 101(10), 2375-2384. ()
28. Gabr A, Kallini JR, Gates VL, Hickey R, Kulik L, Desai K, Thornburg B, Marshall K, Salzig K, Williams M, Del Castillo C, Ganger D, Hohlastos E, Baker T, Lewandowski RJ, Salem R (2016). Same-day 90Y radioembolization: implementing a new treatment paradigm. Eur J Nucl Med Mol Imaging, 43(13), 2353-2359. ()
29. Lewandowski RJ, Andreoli JM, Hickey R, Kallini JR, Gabr A, Baker T, Kircher S, Salem R, Kulik L (2016). Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib. J Vasc Interv Radiol, 27(9), 1329-1336. ()
30. Gordon EJ, Mullee J, Skaro A, Baker T (2016). Live liver donors' information needs: A qualitative study of practical implications for informed consent. Surgery, 160(3), 671-82. ()
31. Lewandowski RJ, Donahue L, Chokechanachaisakul A, Kulik L, Mouli S, Caicedo J, Abecassis M, Fryer J, Salem R, Baker T (2016). (90) Y radiation lobectomy: Outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol, 114(1), 99-105. ()
32. Pomposelli JJ, Goodrich NP, Emond JC, Humar A, Baker TB, Grant DR, Fisher RA, Roberts JP, Olthoff KM, Gillespie BW, Merion RM (2016). Patterns of Early Allograft Dysfunction in Adult Live Donor Liver Transplantation: The A2ALL Experience. Transplantation, 100(7), 1490-9. ()
33. Thornburg B, Desai K, Hickey R, Kulik L, Ganger D, Baker T, Abecassis M, Lewandowski RJ, Salem R (2016). Portal Vein Recanalization and Transjugular Intrahepatic Portosystemic Shunt Creation for Chronic Portal Vein Thrombosis: Technical Considerations. Tech Vasc Interv Radiol, 19(1), 52-60. ()
34. Samstein B, Smith AR, Freise CE, Zimmerman MA, Baker T, Olthoff KM, Fisher RA, Merion RM (2015). Complications and Their Resolution in Recipients of Deceased and Living Donor Liver Transplants: Findings From the A2ALL Cohort Study. Am J Transplant, 16(2), 594-602. ()
35. Wolf JH, Holmes MV, Fouraschen S, Keating BJ, Baker T, Emond J, Rader DJ, Shaked A, Olthoff KM (2015). Serum lipid expression correlates with function and regeneration following living donor liver transplantation. Liver Transpl, 22(1), 103-10. ()
36. Salem R, Vouche M, Baker T, Herrero JI, Caicedo JC, Fryer J, Hickey R, Habib A, Abecassis M, Koller F, Vogelzang R, Desai K, Thornburg B, Hohlastos E, Resnick S, Lewandowski RJ, Sato K, Ryu RK, Ganger D, Kulik L (2015). Pretransplant Portal Vein Recanalization-Transjugular Intrahepatic Portosystemic Shunt in Patients With Complete Obliterative Portal Vein Thrombosis. Transplantation, 99(11), 2347-55. ()
37. Gordon EJ, Mullee J, Butt Z, Kang J, Baker T (2015). Optimizing informed consent in living liver donors: Evaluation of a comprehension assessment tool. Liver Transpl, 21(10), 1270-9. ()
38. Gordon EJ, Rodde J, Skaro A, Baker T (2015). Informed consent for live liver donors: A qualitative, prospective study. J Hepatol, 63(4), 838-47. ()
39. Olthoff KM, Smith AR, Abecassis M, Baker T, Emond JC, Berg CL, Beil CA, Burton JR Jr, Fisher RA, Freise CE, Gillespie BW, Grant DR, Humar A, Kam I, Merion RM, Pomfret EA, Samstein B, Shaked A (2015). Defining long-term outcomes with living donor liver transplantation in North America. Ann Surg, 262(3), 465-75; discussion 473-5. ()
40. Chang Y, Gallon L, Shetty K, Chang Y, Jay C, Levitsky J, Ho B, Baker T, Ladner D, Friedewald J, Abecassis M, Hazen G, Skaro AI (2014). Simulation modeling of the impact of proposed new simultaneous liver and kidney transplantation policies. Transplantation, 99(2), 424-30. ()
41. Emond JC, Fisher RA, Everson G, Samstein B, Pomposelli JJ, Zhao B, Forney S, Olthoff KM, Baker TB, Gillespie BW, Merion RM (2014). Changes in liver and spleen volumes after living liver donation: a report from the Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL). Liver Transpl, 21(2), 151-61. ()
42. Olthoff KM, Emond JC, Shearon TH, Everson G, Baker TB, Fisher RA, Freise CE, Gillespie BW, Everhart JE (2014). Liver regeneration after living donor transplantation: adult-to-adult living donor liver transplantation cohort study. Liver Transpl, 21(1), 79-88. ()
43. Levitsky J, Baker TB, Jie C, Ahya S, Levin M, Friedewald J, Al-Saden P, Salomon DR, Abecassis MM (2014). Plasma protein biomarkers enhance the clinical prediction of kidney injury recovery in patients undergoing liver transplantation. Hepatology, 60(6), 2017-26. ()
44. McElroy LM, Daud A, Davis AE, Lapin B, Baker T, Abecassis MM, Levitsky J, Holl JL, Ladner DP (2014). A meta-analysis of complications following deceased donor liver transplant. Am J Surg, 208(4), 605-18. ()
45. Chang Y, Gallon L, Jay C, Shetty K, Ho B, Levitsky J, Baker T, Ladner D, Friedewald J, Abecassis M, Hazen G, Skaro AI (2013). Comparative effectiveness of liver transplant strategies for end-stage liver disease patients on renal replacement therapy. Liver Transpl, 20(9), 1034-44. ()
46. Kulik L, Vouche M, Koppe S, Lewandowski RJ, Mulcahy MF, Ganger D, Habib A, Karp J, Al-Saden P, Lacouture M, Cotliar J, Abecassis M, Baker T, Salem R (2014). Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. J Hepatol, 61(2), 309-17. ()
47. Memon K, Kulik LM, Lewandowski RJ, Wang E, Wang J, Ryu RK, Hickey R, Vouche M, Baker T, Ganger D, Gates VL, Habib A, Mulcahy MF, Salem R (2014). Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization. J Vasc Interv Radiol, 25(7), 1056-66. ()
48. Vouche M, Habib A, Ward TJ, Kim E, Kulik L, Ganger D, Mulcahy M, Baker T, Abecassis M, Sato KT, Caicedo JC, Fryer J, Hickey R, Hohlastos E, Lewandowski RJ, Salem R (2014). Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology, 60(1), 192-201. ()
49. Vouche M, Kulik L, Atassi R, Memon K, Hickey R, Ganger D, Miller FH, Yaghmai V, Abecassis M, Baker T, Mulcahy M, Nayar R, Lewandowski RJ, Salem R (2013). Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib. Hepatology, 58(5), 1655-66. ()
50. Vouche M, Lewandowski RJ, Atassi R, Memon K, Gates VL, Ryu RK, Gaba RC, Mulcahy MF, Baker T, Sato K, Hickey R, Ganger D, Riaz A, Fryer J, Caicedo JC, Abecassis M, Kulik L, Salem R (2013). Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol, 59(5), 1029-36. ()
51. Salem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, Baker T, Abecassis MM, Atassi R, Riaz A, Cella D, Burns JL, Ganger D, Benson AB 3rd, Mulcahy MF, Kulik L, Lewandowski R (2013). Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol, 11(10), 1358-1365.e1. ()
52. Mouli S, Memon K, Baker T, Benson AB 3rd, Mulcahy MF, Gupta R, Ryu RK, Salem R, Lewandowski RJ (2013). Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol, 24(8), 1227-34. ()
53. Zimmerman MA, Baker T, Goodrich NP, Freise C, Hong JC, Kumer S, Abt P, Cotterell AH, Samstein B, Everhart JE, Merion RM (2012). Development, management, and resolution of biliary complications after living and deceased donor liver transplantation: a report from the adult-to-adult living donor liver transplantation cohort study consortium. Liver Transpl, 19(3), 259-67. ()
54. Leventhal JR, Kocak B, Salvalaggio PR, Koffron AJ, Baker TB, Kaufman DB, Fryer JP, Abecassis MM, Stuart FP (2004). Laparoscopic donor nephrectomy 1997 to 2003: lessons learned with 500 cases at a single institution. Surgery, 136(4), 881-90. ()
55. Heyer EJ, Lee KS, Manspeizer HE, Mongero L, Spanier TB, Caliste X, Esrig B, Smith C (2002). Heparin-bonded cardiopulmonary bypass circuits reduce cognitive dysfunction. J Cardiothorac Vasc Anesth, 16(1), 37-42. ()
56. Mongero LB, Beck JR, Manspeizer HE, Heyer EJ, Lee K, Spanier TA, Smith CR (2001). Cardiac surgical patients exposed to heparin-bonded circuits develop less postoperative cerebral dysfunction than patients exposed to non-heparin-bonded circuits. Perfusion, 16(2), 107-11. ()
57. Spanier T, Tector K, Schwartz G, Chen J, Oz M, Beck J, Mongero L (2000). Endotoxin in pooled pericardial blood contributes to the systemic inflammatory response during cardiac surgery. Perfusion, 15(5), 427-31. ()
58. Williams MR, DAmbra AB, Beck JR, Spanier TB, Morales DL, Helman DN, Oz MC (2000). A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg, 70(3), 873-7. ()
59. Chen JM, Cullinane S, Spanier TB, Artrip JH, John R, Edwards NM, Oz MC, Landry DW (1999). Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable organ donors. Circulation, 100(19 Suppl), II244-6. ()
60. Spanier TB, Chen JM, Oz MC, Stern DM, Rose EA, Schmidt AM (1999). Time-dependent cellular population of textured-surface left ventricular assist devices contributes to the development of a biphasic systemic procoagulant response. J Thorac Cardiovasc Surg, 118(3), 404-13. ()
61. Spanier TB, Chen JM, Mancini DM, Smith CR, Edwards NM (1999). Cardiac transplantation in a patient with protein S deficiency. Ann Thorac Surg, 68(3), 1078-80. ()
62. Ankersmit HJ, Tugulea S, Spanier T, Weinberg AD, Artrip JH, Burke EM, Flannery M, Mancini D, Rose EA, Edwards NM, Oz MC, Itescu S (1999). Activation-induced T-cell death and immune dysfunction after implantation of left-ventricular assist device. Lancet, 354(9178), 550-5. ()
63. Sun BC, Catanese KA, Spanier TB, Flannery MR, Gardocki MT, Marcus LS, Levin HR, Rose EA, Oz MC (1999). 100 long-term implantable left ventricular assist devices: the Columbia Presbyterian interim experience. Ann Thorac Surg, 68(2), 688-94. ()
64. Smith CR, Spanier TB (1999). Aprotinin in deep hypothermic circulatory arrest. Ann Thorac Surg, 68(1), 278-86. ()
65. Chen JM, DeRose JJ, Slater JP, Spanier TB, Dewey TM, Catanese KA, Flannery MA, Oz MC (1999). Improved survival rates support left ventricular assist device implantation early after myocardial infarction. J Am Coll Cardiol, 33(7), 1903-8. ()
66. Chen JM, Spanier TB, Gonzalez JJ, Marelli D, Flannery MA, Tector KA, Cullinane S, Oz MC (1999). Improved survival in patients with acute myocarditis using external pulsatile mechanical ventricular assistance. J Heart Lung Transplant, 18(4), 351-7. ()
67. Spanier TB, Chen JM, Oz MC, Edwards NM, Kisiel W, Stern DM, Rose EA, Schmidt AM (1998). Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass. J Thorac Cardiovasc Surg, 116(5), 860-9. ()
68. Dewey TM, Chen JM, Spanier TB, Oz MC (1999). Alternative technique of right-sided outflow cannula insertion for right ventricular support. Ann Thorac Surg, 66(5), 1829-30. ()
69. Spanier TB, Oz MC, Minanov OP, Simantov R, Kisiel W, Stern DM, Rose EA, Schmidt AM (1998). Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog. J Thorac Cardiovasc Surg, 115(5), 1179-88. ()
70. Spanier T, Smith CR, Burkhoff D (1998). Angiogenesis: a possible mechanism underlying the clinical benefits of transmyocardial laser revascularization. J Clin Laser Med Surg, 15(6), 269-73. ()
71. Spanier TB, Burkhoff D, Smith CR (1998). Role for holmium:YAG lasers in transmyocardial laser revascularization. J Clin Laser Med Surg, 15(6), 287-91. ()
72. Spanier TB, Oz MC, Madigan JD, Rose EA, Stern DM, Nowygrod R, Schmidt AM (1997). Selective anticoagulation with active site blocked factor IXa in synthetic patch vascular repair results in decreased blood loss and operative time. ASAIO J, 43(5), M526-30. ()
73. Spanier T, Oz M, Levin H, Weinberg A, Stamatis K, Stern D, Rose E, Schmidt AM (1996). Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices. J Thorac Cardiovasc Surg, 112(4), 1090-7. ()
74. Spanier TB, Klein RD, Nasraway SA, Rand WM, Rohrer RJ, Freeman RB, Schwaitzberg SD (1995). Multiple organ failure after liver transplantation. Crit Care Med, 23(3), 466-73. ()
75. Nasraway SA, Klein RD, Spanier TB, Rohrer RJ, Freeman RB, Rand WM, Benotti PN (1995). Hemodynamic correlates of outcome in patients undergoing orthotopic liver transplantation. Evidence for early postoperative myocardial depression. Chest, 107(1), 218-24. ()
76. Halpain S, Spanier T, McEwen BS (1986). Loss of 3H-corticosterone binding capacity in hippocampal slices maintained in vitro. Brain Res Bull, 16(2), 167-70. ()

Review

1. Anand K, Cizman Z, Smith T, Strain D, Patel S, Campsen J, Baker T, Saad W (2023). Persistent Bleeding after Coil Embolization of a Pancreatic Transplant Pseudoaneurysm: Should Covered Stents Be the Primary Management? [Review]. Semin Intervent Radiol, 40(3), 283-285. ()
2. Baker T, Tabrizian P, Zendejas I, Gamblin TC, Kazimi M, Boudjema K, Geller D, Salem R (2021). Conversion to resection post radioembolization in patients with HCC: recommendations from a multidisciplinary working group. [Review]. HPB (Oxford), 24(7), 1007-1018. ()

Case Report

1. Siddiqi UA, Hibino N, Combs PS, Baker T, Song T, Kim G, Jeevanandam V (2020). A successful heart and liver transplantation requiring intraoperative extracorporeal membrane oxygenation for primary cardiac allograft dysfunction in a patient with Fontan failure. J Card Surg, 35(6), 1357-1359. ()

Editorial

1. Baker TB (2019). Liver Paired Exchange: Ready for Prime Time in North America? Liver Transpl, 25(11), 1609-1610. ()
2. Baker TB (2016). Living liver donation, donor safety, and social media: Preparing for a new frontier. Liver Transpl, 23(2), 131-132. ()
3. Ladner DP, Baker T (2012). Near-miss events: a vastly missed opportunity. Liver Transpl, 19(5), 467-9. ()
4. Baker TB, Abecassis M, Levitsky J (2012). To kidney or not to kidney, when … is the question. Liver Transpl, 18(8), 875-7. ()

Letter

1. Lambdin J, Ryan CE, Alejandro RH, Baker T, Sapisochin G, Hernandez JM, Al-Adra DP (2022). Neoadjuvant Chemotherapy Plus Living Donor Transplantation (LDLT) for Non-Resectable Liver Metastases from Colorectal Cancer (CRC). [Letter to the editor]. Ann Surg Oncol, 30(1), 18-20. ()
2. Ebong IA, Sayer G, Kim G, Jeevanandam V, Baker T, Becker Y, Fung J, Charlton M, Te H, Josephson M, Uriel N (2019). Simultaneous heart, liver and kidney transplantation: A viable option for heart failure patients with multiorgan failure. [Letter to the editor]. J Heart Lung Transplant, 38(9), 997-999. ()

News

• U of U Health Transplant Programs Announce Record Number of Organ Transplants for 2022